# Schedules of Controlled Substances: Placement of Cipepofol in Schedule IV

**Action Urgency Score:** 30/100

| Field | Value |
|---|---|
| Agency | Justice Department; Drug Enforcement Administration |
| Type | Final rule |
| Action | Interim final rule; request for comments. |
| Published | 2026-08-27 |
| Effective | 2026-08-27 |
| Comments close | 2026-09-28 |
| Significant | No |
| CFR parts | 21 CFR 1308 |
| Summary | On May 29, 2026, the United States Food and Drug Administration (FDA) approved a new drug application for Cypsedo (cipepofol) for induction of general anesthesia in adults undergoing surgery. The Department of Health and Human Services provided the Drug Enforcement Administration (DEA) with a scheduling recommendation to place cipepofol, chemically known as 2-[(1R)-1-cyclopropylethyl]-6- isopropylphenol, in schedule IV of the Controlled Substances Act (CSA). In accordance with the CSA, as amended by the Improving Regulatory Transparency for New Medical Therapies Act, DEA is hereby issuing an i |
| Document number | 2026-17536 |

## Why this score
- Final rule.

Source: Federal Register API (Office of the Federal Register) (https://www.federalregister.gov/documents/2026/08/27/2026-17536/schedules-of-controlled-substances-placement-of-cipepofol-in-schedule-iv). Last refreshed: 2026-11-04T09:17:43.641Z.
Data from the Federal Register API; the published Federal Register document is authoritative. Informational only, not legal advice.